This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
HAYES, Inc.. Magnetic resonance-guided focused ultrasound therapy (ExAblate 2000; InSightec Ltd.) for ablation of uterine fibroids. Lansdale: HAYES, Inc.. Healthcare Technology Brief Publication. 2016
Description of Technology: Magnetic resonance–guided focused ultrasound (MRgFUS) combines thermal effects (due to absorption of acoustic energy) with magnetic resonance imaging to treat symptomatic uterine fibroids. Thermal ablation by MRgFUS causes cell death and coagulative necrosis of the targeted tissue while sparing surrounding organs. MRgFUS ablation of uterine fibroids is performed by a board-certified interventional radiologist on an outpatient basis.
Patient Population: MRgFUS is indicated to ablate uterine fibroid tissue in premenopausal or perimenopausal women with symptomatic uterine fibroids who desire a uterine-sparing procedure and whose uterine size is less than 24 weeks gestation size.
Subject indexing assigned by CRD
Female; Humans; Leiomyoma; Magnetic Resonance Spectroscopy; Uterine Neoplasms
Country of organisation
An English language summary is available.
Address for correspondence
HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: email@example.com
Date abstract record published